Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $480.49M
Last updated: Nov 17, 2026 at 4:10 PM ET
Gyre Therapeutics Inc. (GYRE) Statistics
Gyre Therapeutics (GYRE) has a market cap of $480.49M and an enterprise value of $438.85M. Its share count is up 17.01% from a year earlier. It kept -22.97% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 8.67% below the market cap, as cash exceeds debt.
| Market Cap | $480.49M |
|---|---|
| Enterprise Value | $438.85M |
| Latest price (Nov 17, 2026) | $4.56 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.0x and 4.5x. Its year-end P/S ranged from 1.0x to 35.8x from 2016 to 2025.
| P/S Ratio | 4.0x |
|---|---|
| Forward P/S | 4.3x |
| P/B Ratio | 4.5x |
| P/TBV Ratio | 4.7x |
Price Statistics
The stock is down 42.93% over 52 weeks and trades 26.45% below its 50-day average.
| Beta (1Y) | 1.63 |
|---|---|
| 52-Week Change | -42.93% |
| 1-Month Change | -25.12% |
| 3-Month Change | -36.22% |
| 6-Month Change | -27.16% |
| 5-Year Change | -64.88% |
| 10-Year Change | -89.30% |
| Total Return (1Y) | -42.93% |
| Total Return (3Y CAGR) | -32.32% |
| Total Return (5Y CAGR) | +10.88% |
| Return vs SPY (1Y) | -52.11% |
| Max Drawdown (1Y) | -54.22% |
| Max Drawdown (3Y) | -86.49% |
| Sharpe Ratio (1Y) | -0.76 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $6.20 |
| 200-Day Average | $6.77 |
| 52-Week Range | $3.97 to $9.14 |
| RSI (14 Days) | 39.8 |
| Average Volume (20 Days) | 226.53K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.32x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.32x |
|---|---|
| Quick Ratio | 3.89x |
| Debt / Equity | 0.00x |
| Interest Coverage | -7.26x |
Returns and Efficiency
Return on equity is -25.91% and return on assets is -13.90% over the last 12 months.
| Return on Equity (ROE) | -25.91% |
|---|---|
| Return on Assets (ROA) | -13.90% |
| ROA (5Y Average) | -41.49% |
| ROIC (5Y Average) | 13.90% |
| Asset Turnover | 0.68x |
| Inventory Turnover | 0.60x |
| Receivables Turnover | 4.00x |
| Cash Conversion Cycle | 598 days |
Scores
GYRE has an Altman Z-Score of 7.98, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.98 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $121.75M over the last 12 months is up 8.36% from the 12 months before.
| Revenue | $121.75M |
|---|---|
| Revenue Growth (YoY) | +8.36% |
| Gross Profit | $114.63M |
| Operating Income | -$25.12M |
| Pretax Income | -$25.48M |
| Net Income | -$27.97M |
| Reported EPS (TTM) | -$0.13 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 53.64% of the $201.25M in total assets.
| Cash and Equivalents | $41.64M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.64M |
| Net Cash Per Share | $0.39 |
| Working Capital | $94.81M |
| Shareholder Equity | $107.95M |
| Book Value Per Share | $1.02 |
| Tangible Book Value | $103.55M |
| Tangible Book Per Share | $0.97 |
| Total Assets | $201.25M |
| Total Liabilities | $35.18M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.56M of capital spending, operating cash flow left -$24.72M of free cash flow.
| Operating Cash Flow | -$23.16M |
|---|---|
| Capital Expenditures | $1.56M |
| Free Cash Flow | -$24.72M |
| FCF Per Share | -$0.23 |
| Depreciation and Amortization | $3.28M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -20.63%.
| Gross Margin | 94.15% |
|---|---|
| Operating Margin | -20.63% |
| Pretax Margin | -20.93% |
| Net Margin | -22.97% |
| FCF Margin | -20.30% |
| Gross Margin (5Y Average) | 76.47% |
Growth
Revenue grew 4.46% a year over 3 years.
| Revenue Growth (3Y CAGR) | +4.46% |
|---|---|
| Revenue Growth (5Y CAGR) | +40.96% |
| Operating Income Growth (3Y CAGR) | +7.67% |
Dividends and Yields
GYRE does not pay a dividend. Its free cash flow yield is -5.10%.
| FCF Yield | -5.10% |
|---|---|
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-15 reverse split on Oct 31, 2023.
| Last Split Date | Oct 31, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Peer Position
Against 7 similar companies, GYRE has the 6th highest P/S.
P/S RatioPeer median 8.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -39.51%
| P/S Ratio | 4.0x vs 8.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.36% vs -39.51% median |
Analyst Forecast
Consensus estimates put revenue growth at 12.36% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +12.36% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GYRE
What is GYRE's market cap?
Gyre Therapeutics has a market cap of $480.49M. Its enterprise value, which adds debt and subtracts cash, is $438.85M.
How many shares of GYRE are outstanding?
Gyre Therapeutics has 106.30M shares outstanding. The count is up 17.01% from a year earlier.
Does GYRE pay a dividend?
No. Gyre Therapeutics does not pay a dividend.
How much debt does GYRE have?
Gyre Therapeutics has $0 of total debt and $41.64M of cash and equivalents, a net cash position of $41.64M.
GYRE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors